In clear-cell renal cell carcinoma (ccRCC), inactivation of the tumor suppressor von Hippel-Lindau (VHL) occurs in the majority of the tumors and is causal for the pathogenesis of ccRCC. Recently, a large-scale genomic sequencing study of ccRCC tumors revealed that enzymes that regulate histone H3 lysine 4 trimethylation (H3K4Me3), such as JARID1C/KDM5C/SMCX and MLL2, were mutated in ccRCC tumors, suggesting that H3K4Me3 might have an important role in regulating gene expression and tumorigenesis. In this study we report that in VHL-deficient ccRCC cells, the overall H3K4Me3 levels were significantly lower than that of VHL+/+ counterparts. Furthermore, this was hypoxia-inducible factor (HIF) dependent, as depletion of HIF subunits by small hairpin RNA in VHL-deficient ccRCC cells restored H3K4Me3 levels. In addition, we demonstrated that only loss of JARID1C, not JARID1A or JARID1B, abolished the difference of H3K4Me3 levels between VHL-/- and VHL+/+ cells, and JARID1C displayed HIF-dependent expression pattern. JARID1C in VHL-/- cells was responsible for the suppression of HIF-responsive genes insulin-like growth factor-binding protein 3 (IGFBP3), DNAJC12, COL6A1, growth and differentiation factor 15 (GDF15) and density-enhanced phosphatase 1. Consistent with these findings, the H3K4Me3 levels at the promoters of IGFBP3, DNAJC12, COL6A1 and GDF15 were lower in VHL-/- cells than in VHL+/+ cells, and the differences disappeared after JARID1C depletion. Although HIF2α is an oncogene in ccRCC, some of its targets might have tumor suppressive activity. Consistent with this, knockdown of JARID1C in 786-O VHL-/- ccRCC cells significantly enhanced tumor growth in a xenograft model, suggesting that JARID1C is tumor suppressive and its mutations are tumor promoting in ccRCC. Thus, VHL inactivation decreases H3K4Me3 levels through JARID1C, which alters gene expression and suppresses tumor growth.
In clear-cell renal cell carcinoma (ccRCC), inactivation of the pan class="Disease">tumor suppressor von Hippel-Lindau (VHL) occurs in the majority of the tumors and is causal for the pathogenesis of ccRCC. Recently, a large-scale genomic sequencing study of ccRCC tumors revealed that enzymes that regulate histone H3lysine 4 trimethylation (H3K4Me3), such as JARID1C/KDM5C/SMCX and MLL2, were mutated in ccRCC tumors, suggesting that H3K4Me3 might have an important role in regulating gene expression and tumorigenesis. In this study we report that in VHL-deficient ccRCC cells, the overall H3K4Me3 levels were significantly lower than that of VHL+/+ counterparts. Furthermore, this was hypoxia-inducible factor (HIF) dependent, as depletion of HIF subunits by small hairpin RNA in VHL-deficient ccRCC cells restored H3K4Me3 levels. In addition, we demonstrated that only loss of JARID1C, not JARID1A or JARID1B, abolished the difference of H3K4Me3 levels between VHL-/- and VHL+/+ cells, and JARID1C displayed HIF-dependent expression pattern. JARID1C in VHL-/- cells was responsible for the suppression of HIF-responsive genes insulin-like growth factor-binding protein 3 (IGFBP3), DNAJC12, COL6A1, growth and differentiation factor 15 (GDF15) and density-enhanced phosphatase 1. Consistent with these findings, the H3K4Me3 levels at the promoters of IGFBP3, DNAJC12, COL6A1 and GDF15 were lower in VHL-/- cells than in VHL+/+ cells, and the differences disappeared after JARID1C depletion. Although HIF2α is an oncogene in ccRCC, some of its targets might have tumor suppressive activity. Consistent with this, knockdown of JARID1C in 786-O VHL-/- ccRCC cells significantly enhanced tumor growth in a xenograft model, suggesting that JARID1C is tumor suppressive and its mutations are tumor promoting in ccRCC. Thus, VHL inactivation decreases H3K4Me3 levels through JARID1C, which alters gene expression and suppresses tumor growth.
Authors: Shigeki Iwase; Fei Lan; Peter Bayliss; Luis de la Torre-Ubieta; Maite Huarte; Hank H Qi; Johnathan R Whetstine; Azad Bonni; Thomas M Roberts; Yang Shi Journal: Cell Date: 2007-02-22 Impact factor: 41.582
Authors: Peter Schraml; Ian J Frew; Claudio R Thoma; Gunther Boysen; Kirsten Struckmann; Wilhelm Krek; Holger Moch Journal: Mod Pathol Date: 2008-07-25 Impact factor: 7.842
Authors: Olga Mikhaylova; Monika L Ignacak; Teresa J Barankiewicz; Svetlana V Harbaugh; Ying Yi; Patrick H Maxwell; Martin Schneider; Katie Van Geyte; Peter Carmeliet; Monica P Revelo; Michael Wyder; Kenneth D Greis; Jarek Meller; Maria F Czyzyk-Krzeska Journal: Mol Cell Biol Date: 2008-02-19 Impact factor: 4.272
Authors: Sven Wellmann; Maxi Bettkober; Andrea Zelmer; Karl Seeger; Marion Faigle; Holger K Eltzschig; Christoph Bührer Journal: Biochem Biophys Res Commun Date: 2008-06-04 Impact factor: 3.575
Authors: Patrick J Pollard; Christoph Loenarz; David R Mole; Michael A McDonough; Jonathan M Gleadle; Christopher J Schofield; Peter J Ratcliffe Journal: Biochem J Date: 2008-12-15 Impact factor: 3.857
Authors: Haifeng Yang; Yoji Andrew Minamishima; Qin Yan; Susanne Schlisio; Benjamin L Ebert; Xiaoping Zhang; Liang Zhang; William Y Kim; Aria F Olumi; William G Kaelin Journal: Mol Cell Date: 2007-10-12 Impact factor: 17.970
Authors: Xiaobo Xia; Madeleine E Lemieux; Wei Li; Jason S Carroll; Myles Brown; X Shirley Liu; Andrew L Kung Journal: Proc Natl Acad Sci U S A Date: 2009-03-02 Impact factor: 11.205
Authors: Ponniah Selvakumar; Tori A Owens; Justin M David; Nicholas J Petrelli; Brock C Christensen; Ashakumary Lakshmikuttyamma; Ayyappan K Rajasekaran Journal: Epigenetics Date: 2014-01-22 Impact factor: 4.528
Authors: James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer Journal: Eur Urol Date: 2016-10-15 Impact factor: 20.096